Are you Dr. Fordyce?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 60 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
550 1st Ave
Room 16n30-Bh
New York, NY 10016Phone+1 212-562-6401
Summary
- Dr. Marshall Fordyce, MD is an infectious disease specialist in New York, New York. He is currently licensed to practice medicine in New York and California.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Infectious Disease, 2008 - 2010
NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2008
Harvard Medical SchoolClass of 2004
Certifications & Licensure
CA State Medical License 2011 - 2025
NY State Medical License 2006 - 2011
Clinical Trials
- Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Start of enrollment: 2010 Apr 01
- Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults Start of enrollment: 2011 Sep 01
- Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment Start of enrollment: 2013 Mar 27
Publications & Presentations
PubMed
- 46 citationsA Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infec...Gregory D Huhn, Pablo Tebas, Joel E. Gallant, Timothy J. Wilkin, Andrew K. Cheng
Journal of Acquired Immune Deficiency Syndromes. 2017-02-01 - 207 citationsCurrent status and prospects of HIV treatment.Tomas Cihlar, Marshall Fordyce
Current Opinion in Virology. 2016-06-01 - 57 citationsPharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.Joseph M. Custodio, Marshall W. Fordyce, William Garner, Mona Vimal, Kah Hiing J. Ling
Antimicrobial Agents and Chemotherapy. 2016-09-01
Press Mentions
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 Mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in ProteinuriaJanuary 30th, 2023- Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA NephropathyJanuary 4th, 2023
- Vera Therapeutics Appoints Industry Veteran Dr. Celia Lin as Chief Medical OfficerApril 20th, 2021
- Join now to see all
